A Phase I, Open-label, Excretion Balance, Pharmacokinetic and Metabolism Stud After Single Oral Dose of 14C-labeled RO5185426 in Previously Treated and Untreated Patients With Metastatic Melanoma
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2016
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Pharmacokinetics
- Sponsors Roche
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Sep 2012 Planned end date changed from 1 Jul 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 15 Mar 2011 Planned end date changed from 1 Apr 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.